Detail akcie Apellis Pharma Rg online

Business Summary: Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Apellis Pharmaceuticals Inc revenues decreased 3% to $166.8M. Net loss increased 39% to $92.2M. Revenues reflect SYFOVRE segment decrease of 5% to $130.2M, EMPAVELI segment decrease of 23% to $19.7M. Higher net loss reflects Compensation and related personnel costs increase of 3% to $33.5M (expense), Research and Development - Balancing val increase of 2% to $53M (expense).